Raspollini Maria Rosaria, Castiglione Francesca, Garbini Francesca, Villanucci Alessandro, Amunni Gianni, Baroni Gianna, Boddi Vieri, Taddei Gian Luigi
Department of Human Pathology and Oncology, University of Florence, School of Medicine, Florence, Italy.
Int J Surg Pathol. 2005 Apr;13(2):135-42. doi: 10.1177/106689690501300202.
We analyzed in advanced ovarian serous G3 carcinoma the correlation between epidermal growth factor receptor (EGFR) overexpression and tumor angiogenesis and their relation with clinical outcome. Microvessel density (MVD) and vascular endothelial growth factor (VEGF) were statistically correlated with disease-free interval and death from disease both in univariate and multivariate analyses while EGFR expression was not correlated with clinical outcome. MVD was significantly associated with progression of disease during chemotherapy while VEGF and EGFR expression were not correlated with responsiveness to chemotherapy (Fisher's exact test). VEGF expression was correlated with MVD (Fisher's exact test). EGFR showed a trend to correlation with MVD. Further studies focusing on the use of angiogenesis inhibitors in addition to EGFR inhibitors on ovarian carcinoma cells may produce therapeutic strategies in the selection of tailored therapies in ovarian cancer patients.
我们分析了晚期卵巢浆液性G3癌中表皮生长因子受体(EGFR)过表达与肿瘤血管生成之间的相关性,以及它们与临床结局的关系。在单变量和多变量分析中,微血管密度(MVD)和血管内皮生长因子(VEGF)与无病生存期和疾病死亡均存在统计学相关性,而EGFR表达与临床结局无关。MVD与化疗期间疾病进展显著相关,而VEGF和EGFR表达与化疗反应性无关(Fisher精确检验)。VEGF表达与MVD相关(Fisher精确检验)。EGFR显示出与MVD相关的趋势。进一步研究除了在卵巢癌细胞上使用EGFR抑制剂外,还使用血管生成抑制剂,可能会为卵巢癌患者量身定制治疗方案的选择产生治疗策略。